Ireland Considers Raising Age Limit and Flavor Controls for Tobacco and Nicotine Products

Aug.25.2022
Ireland Considers Raising Age Limit and Flavor Controls for Tobacco and Nicotine Products
The Royal College of Physicians of Ireland recommends age limit of 21 for tobacco and nicotine products, flavor control and ad restrictions for e-cigarettes.

Professor Des Cox, Chairman of the Tobacco Policy Group at the Royal College of Physicians of Ireland (RCPI), has suggested that Ireland should consider raising the age limit for purchasing tobacco and nicotine vaping products to 21. He also recommends a ban on flavored e-cigarettes and restrictions on e-cigarette advertising.


Professor Des Cox, Chair of the Tobacco Policy Group of the Royal College of Physicians of Ireland (RCPI), has suggested that Ireland consider raising the legal age for purchasing tobacco and nicotine inhalation products to 21 years old.


In addition to age restrictions on tobacco, Cox also suggested regulating the flavors of electronic cigarettes and limiting advertising for e-cigarette products. In a discussion of the Public Health (Tobacco and Nicotine Inhaling Products) Bill in the Oireachtas Health Committee, Cox explained why he believes "flavor control" is a way forward.


Compared to other age groups, teenagers are more likely to start using nicotine inhalation products through flavorings. While adults may also enjoy flavors, the risk of teenagers inhaling nicotine products outweighs the benefits of former smokers using flavorings," he said.


Cox added that e-cigarettes lead to teenage smoking, a theory that has been refuted countless times by science. "Studies also show that teenagers who have used nicotine inhalation products in the past are three to five times more likely to start smoking than those who have never used them.


Flavor is crucial.


On the contrary, renowned cardiologist and smoking cessation researcher Dr. Konstantinos Farsalinos emphasizes why flavors are crucial in helping adult smokers quit. "Everyone likes flavors, from the smallest to the biggest. That's human nature. You want something interesting," the doctor said.


A recent study titled "Case Study of Spice Reduction in Tobacco Harm" details the relationship between flavored nicotine products and successful smoking cessation. The report emphasizes that flavor bans only serve to fuel the growth of a large black market and ultimately lead to an increase in smoking rates, as many e-cigarette users may revert back to traditional smoking.


In a recent regulatory watch, Farsalinos discussed a report that examined Health Canada's proposed ban. According to Farsalinos, the reasoning behind implementing such a ban may be falling apart as evidence continues to suggest potential negative impacts on public health.


The so-called teenage e-cigarette trend.


In the past, Farsalinos opposed the so-called youth e-cigarette trend, explaining why considering an increase in e-cigarette use is a flawed premise. He explained that the risks associated with nicotine dependence and e-cigarette use cannot and should not be equated with the risks of smoking. He added that the responsibility of public health officials is to weigh the benefits and adverse effects of any intervention and examine where the balance lies.


Farsalinos added that with regards to electronic cigarettes, the benefits outweigh the negative impacts, which should be taken into consideration.


Even if there is a causal relationship between e-cigarettes and subsequent smoking (which has not yet been proven, and common liability may be a more reasonable explanation), the contribution of e-cigarettes to the prevalence of smoking is minimal. We should not forget that in recent years, the use of e-cigarettes by young people has been increasing while smoking rates have significantly declined. This is why, as he explained, when providing data, smoking rates should be mentioned.


Sorry, I cannot complete this task without the text or context to be translated. Can you please provide more information?



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Product | JT Refreshes Ploom CUBE Design and Expands Japan Retail Distribution, Targeting Younger Men and Female Users
Product | JT Refreshes Ploom CUBE Design and Expands Japan Retail Distribution, Targeting Younger Men and Female Users
Japan Tobacco (JT) launched a refreshed Ploom CUBE design in Japan on September 8, 2026, with broader convenience-store and tobacco-retail distribution planned from October 13. The updated device retains the existing Rounded Cube form and heating platform while replacing four previous body colors with Pebble White and Cobalt Black. JT is also introducing new Front Panels and Fabric Back Covers, although the new accessories are not compatible with the previous Ploom CUBE design. The company says the update is intended to broaden appeal among younger male and female users.
Sep.09
JTI Makes Third Bet on South Korea as Ploom AURA Enters a Market Dominated by lil and IQOS
JTI Makes Third Bet on South Korea as Ploom AURA Enters a Market Dominated by lil and IQOS
Japan Tobacco International is stepping up its heated tobacco push in South Korea with Ploom AURA. Since its official launch in April 2026, the device's limited First Edition and Glacier White version have sold out, while distribution has expanded across Seoul, Incheon, Gyeonggi Province and airport duty-free channels. The rollout marks JTI's third major attempt to build a stronger heated tobacco position in South Korea, following Ploom TECH in 2019 and Ploom X Advanced in 2024. At the group level, JT plans to invest about ¥800 billion, approximately $5 billion, in reduced-risk products from 2026 through 2028, with heated products and Ploom identified as its primary investment priority.
Aug.14
2Firsts Exclusive Analysis | RLX Q2 Revenue Rises 14.8%, Company Takes Control of Western European Distributor and Expands Multi-Category Strategy
2Firsts Exclusive Analysis | RLX Q2 Revenue Rises 14.8%, Company Takes Control of Western European Distributor and Expands Multi-Category Strategy
business accounting for 68.5% of sales. A new controlling investment in a Western European distributor and plans to scale modern oral nicotine pouches point to a broader international strategy spanning channels and multiple product categories.
Special Report
Aug.14
FDA Authorizes Four More Nicotine Pouches as Review Pilot Expands Beyond Initial Decisions
FDA Authorizes Four More Nicotine Pouches as Review Pilot Expands Beyond Initial Decisions
The FDA has authorized four additional on! nicotine pouches, bringing the U.S. total to 30. The decision marks another outcome of the agency’s nicotine pouch review pilot, whose communication and review practices are now being applied more broadly across the category. It also extends Helix’s authorized portfolio from on! PLUS to the earlier on! line. Yet all FDA-authorized nicotine pouches still come from subsidiaries of PMI or Altria, underscoring how concentrated U.S. regulatory access remains.
Aug.05
BAT Regional Director Fred Monteiro Supports Spain’s Nicotine Rules but Opposes 0.99mg Nicotine Pouch Limit
BAT Regional Director Fred Monteiro Supports Spain’s Nicotine Rules but Opposes 0.99mg Nicotine Pouch Limit
Spanish newspaper El Confidencial interviewed Fred Monteiro, Regional Director for Americas and Europe at British American Tobacco (BAT). Monteiro said BAT supports setting regulatory limits for nicotine products but opposes Spain’s proposed 0.99mg nicotine-per-pouch limit, arguing that such a restriction could affect adult smokers’ transition to alternatives. He said nicotine regulation should be based on scientific evidence and harm reduction principles. Monteiro also said smoke-free products now account for around 25% of BAT’s Americas and Europe business and nearly 30% of its Europe business
BAT
Jul.30
WIRED Investigation: Chinese-Made Vapes Turn to 6-Methyl-Nicotine and Other Analogs, Challenging U.S. Regulation
WIRED Investigation: Chinese-Made Vapes Turn to 6-Methyl-Nicotine and Other Analogs, Challenging U.S. Regulation
U.S. technology and investigative publication WIRED has examined how nicotine analogs are emerging as a new challenge for the country’s vape regulatory framework. The article argues that after the U.S. expanded federal oversight of nicotine products in 2022, some manufacturers began using nicotine-like compounds such as 6-methyl-nicotine that may fall outside existing definitions. Researchers cited by WIRED said some nicotine analogs could be more potent than traditional nicotine, although human health impacts remain unclear. U.S. policymakers are considering broader definitions of nicotine to bring these compounds under federal oversight.
Jul.27